<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00234949</url>
  </required_header>
  <id_info>
    <org_study_id>M04-699</org_study_id>
    <nct_id>NCT00234949</nct_id>
  </id_info>
  <brief_title>A Study to Compare Cefdinir and Cephalexin for the Treatment of Mild to Moderate Uncomplicated Skin Infections</brief_title>
  <official_title>A Comparative Study of the Safety, Tolerability, and Efficacy of Cefdinir and Cephalexin for the Treatment of Subjects With Mild to Moderate Uncomplicated Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and tolerability of cefdinir to that of&#xD;
      cephalexin in patients with mild to moderate uncomplicated skin/skin structure infections.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical cure rate</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event rates</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bacteriologic cure rates</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
  </secondary_outcome>
  <enrollment>380</enrollment>
  <condition>Mild to Moderate Uncomplicated Skin and Skin Structure Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefdinir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cephalexin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory male or female subjects &gt; 13 years old.&#xD;
&#xD;
          -  A female subject must be non-lactating and at no risk for pregnancy.&#xD;
&#xD;
          -  Diagnosis of USSSI with 2 or more of the following local signs and symptoms:&#xD;
&#xD;
               -  Pain/tenderness&#xD;
&#xD;
               -  Swelling&#xD;
&#xD;
               -  Erythema&#xD;
&#xD;
               -  Localized warmth&#xD;
&#xD;
               -  Purulent drainage/discharge&#xD;
&#xD;
               -  Induration&#xD;
&#xD;
               -  Regional lymph node swelling or tenderness&#xD;
&#xD;
               -  Extension of redness&#xD;
&#xD;
          -  Acceptable USSSI include, but are not limited to:&#xD;
&#xD;
               -  Cellulitis&#xD;
&#xD;
               -  Erysipelas&#xD;
&#xD;
               -  Impetigo&#xD;
&#xD;
               -  Simple abscess&#xD;
&#xD;
               -  Wound infection&#xD;
&#xD;
               -  Furunculosis&#xD;
&#xD;
               -  Folliculitis&#xD;
&#xD;
          -  A sample for microbiologic culture must be obtained from the primary infection site&#xD;
             within 48 hours prior to study drug administration.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Medical history of hypersensitivity or allergic reaction to penicillin and/or&#xD;
             cephalosporin (including cefdinir and cephalexin) antibiotics according to the&#xD;
             judgment of the Investigator.&#xD;
&#xD;
          -  Subject with a complicated skin and skin structure infection as judged by the&#xD;
             investigator.&#xD;
&#xD;
          -  A chronic or underlying skin condition at the site of infection (e.g., a secondary&#xD;
             infected atopic dermatitis or eczema) or infections involving prosthetic materials&#xD;
             (e.g., catheter tunnel infections, orthopedic hardware).&#xD;
&#xD;
          -  A wound secondary to burn injury or acne vulgaris.&#xD;
&#xD;
          -  Any infection site that requires:&#xD;
&#xD;
               -  intraoperative surgical debridement;&#xD;
&#xD;
               -  excision of infected lesions or body parts.&#xD;
&#xD;
          -  Infections that can be treated by surgical incision alone according to the judgment of&#xD;
             the Investigator.&#xD;
&#xD;
          -  Any other infection that necessitates the use of additional concomitant oral or&#xD;
             parenteral antibiotic therapy.&#xD;
&#xD;
          -  Known significant renal or hepatic impairment indicated by:&#xD;
&#xD;
               -  Serum Creatinine &gt; 2.0 mg/dL (176.8 mol/L)&#xD;
&#xD;
               -  SGOT (AST) &gt; 3x the upper limit of the reference range&#xD;
&#xD;
               -  SGPT (ALT) &gt; 3x the upper limit of the reference range&#xD;
&#xD;
               -  Alkaline Phosphatase &gt; 2x the upper limit of the reference range&#xD;
&#xD;
               -  Total Bilirubin &gt; 2x the upper limit of the reference range&#xD;
&#xD;
          -  Underlying condition and/or disease that, according to the judgment of the&#xD;
             Investigator, would be likely to interfere with completion of the course of study drug&#xD;
             therapy or follow-up.&#xD;
&#xD;
          -  The Investigator considers the subject an unsuitable candidate for cefdinir or&#xD;
             cephalexin administration&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Medical Information</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>October 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2005</study_first_posted>
  <last_update_submitted>October 23, 2007</last_update_submitted>
  <last_update_submitted_qc>October 23, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2007</last_update_posted>
  <keyword>Cefdinir</keyword>
  <keyword>Cephalexin</keyword>
  <keyword>Skin Infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalexin</mesh_term>
    <mesh_term>Cefdinir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

